SQZ’s Point-of-Care (POC) Manufacturing
Platform Shows Promising Results with Ability to Produce Cell
Therapies at Scale in Under 10 Hours
Co-Development of Research-Use-Only System with
STEMCELL Technologies to Help Drive Cell Therapy Innovation by the
Broader Scientific Community
Presentations on the POC Manufacturing
Platform, Research Scale System and Hematopoietic Stem Cell
Engineering Preclinical Data at 2022 American Society for Gene and
Cell Therapy Annual Meeting
SQZ Biotechnologies (NYSE: SQZ) announced today that the company
will present data from the first non-clinical studies of its
point-of-care (POC) manufacturing system at the 2022 American
Society for Gene and Cell Therapy (ASGCT) Annual Meeting on May 18.
The data will demonstrate an ability to produce SQZ® cell therapy
candidates with comparable or improved performance relative to
conventional clean room manufacturing processes. In addition, SQZ
announced a collaboration with STEMCELL Technologies to co-develop
and commercialize a research-use-only (RUO) microfluidic
intracellular delivery system. The new RUO system will be based on
SQZ’s Cell Squeeze® technology and will offer the life sciences
community access to a unique cell engineering capability to advance
preclinical research. These activities support SQZ’s mission to
unlock the full potential of cell therapies for multiple
therapeutic areas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220505005207/en/
SQZ Biotechnologies CEO and Founder Armon
Sharei, PhD holds examples of manufacturing (L) and research (R)
Cell Squeeze® chips. (Photo: Business Wire)
“SQZ’s vision is to improve patient care by creating
transformative cell therapies that can be broadly accessible around
the world through rapid, cost-efficient manufacturing,” said Armon
Sharei, Ph.D., CEO and Founder at SQZ Biotechnologies. “We are
advancing these important goals through the development of our POC
manufacturing system, which has the potential to substantially
improve the accessibility and economic feasibility of cell
therapies. Through our collaboration with STEMCELL, we intend to
broaden technology access for research use and hope to facilitate
advancement of the cell therapy field by the life sciences
community.”
“This is an exciting collaboration that combines STEMCELL’s life
sciences research and product development capabilities with SQZ’s
cell engineering expertise,” said Allen Eaves, M.D., Ph.D.,
President and CEO of STEMCELL Technologies. “The development of
this RUO system, which will be well complemented by our various
cell isolation and culture product portfolios, will provide the
research community with a significant opportunity for their cell
engineering investigations. By adapting the proven Cell Squeeze®
technology, with its ability to deliver multiple biological cargoes
to a range of cell types, we anticipate the RUO system will offer
enhanced flexibility to the scientific community. We look forward
to our continued collaboration with SQZ and the development of this
system.”
SQZ’s Cell Squeeze® technology has enabled the development of
three oncology therapeutic candidates in active Phase 1/2 clinical
trials. In addition to these programs, the company intends to file
its first IND using the POC system for a SQZ® TAC clinical
candidate against celiac disease in the first half of 2023. The
Cell Squeeze® technology has also led to a number of preclinical
developments in the areas of infectious disease and cell
regeneration.
SQZ’s automated POC manufacturing system in development
integrates, among other things, cell isolation, cell washing,
intracellular delivery, and product filling. The system is designed
to process patient material within a closed, single-use sterile
disposable kit. The prototype system offers the potential to be
operated outside of a clean room—which could ultimately allow
decentralized cell therapy manufacturing by SQZ® POC systems in a
variety of care settings. SQZ will present data from the initial
non-clinical studies of the POC system at ASGCT.
STEMCELL Technologies will present data from the first
functional study findings for the RUO system at the ASGCT Annual
Meeting. The data will demonstrate an ability to efficiently
deliver cargoes to primary immune cell types. SQZ will also present
new cell engineering data in hematopoietic stem cells using mRNA
and CRISPR/Cas9 at the meeting.
ASGCT PRESENTATION TITLES AND TIMING
SQZ Point-of-Care Manufacturing Presentation Title: A
Decentralized and Integrated Manufacturing System for the Rapid and
Cost-Effective Production of Cell Therapy Drug Products SQZ
Presenter: Maisam Dadgar Session Title: Cell Therapy
Product Engineering, Development or Manufacturing Abstract
Number: 1171 Date & Time: Wednesday, May 18, 2022,
from 5:30-6:30 PM
STEMCELL TECHNOLOGIES Immune Cell Engineering Research Poster
Presentation Title: A New Benchtop System for Simple and
Versatile Introduction of Macromolecules into Human Lymphocytes by
Microfluidic Squeezing STEMCELL Presenter: Eric Ouellet,
Ph.D. Session Title: Synthetic/Molecular Conjugates and
Physical Methods for Delivery II Abstract Number: 997
Date & Time: Wednesday, May 18, 2022, from 5:30-6:30
PM
SQZ Hematopoietic Stem Cell Research Title: Rapid,
Gentle, and Scalable Engineering of Hematopoietic Stem Cells Using
Vector-Free Microfluidic Cell Squeeze® Technology SQZ
Presenter: Murillo Silva, Ph.D. Session Title: Cell
Therapy Product Engineering, Development or Manufacturing
Abstract Number: 1176 Date & Time: Wednesday, May
18, 2022, from 5:30-6:30 PM
About SQZ Biotechnologies SQZ Biotechnologies Company is
a clinical-stage biotechnology company focused on unlocking the
full potential of cell therapies for patients around the world and
has active programs in oncology, autoimmune and infectious
diseases, as well as additional exploratory initiatives to support
future pipeline growth. The company’s proprietary Cell Squeeze®
technology offers the unique ability to deliver multiple biological
materials into many cell types to engineer what we believe can be a
broad range of potential therapeutics. With demonstrated production
timelines under 24 hours and the opportunity to eliminate
preconditioning and lengthy hospital stays, our approach could
significantly broaden the therapeutic range and accessibility of
cell therapies. The company’s first therapeutic applications seek
to generate target-specific immune responses, both in activation
for the treatment of solid tumors and infectious diseases, and in
immune tolerance for the treatment of autoimmune diseases. For more
information, please visit www.sqzbiotech.com.
About STEMCELL Technologies STEMCELL Technologies
supports life sciences research with more than 2,500 specialized
reagents, tools, and services. STEMCELL offers high-quality cell
culture media, cell separation technologies, instruments, accessory
products, educational resources, and contract assay services that
are used by scientists performing stem cell, immunology, cancer,
regenerative medicine, and cellular therapy research globally. To
learn more and receive future announcements about the RUO system in
development, visit www.stemcell.com/RUOsystem.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements relating to events and presentations, our platform
development, our product candidates, preclinical and clinical
activities, progress and outcomes, development plans, manufacturing
systems, clinical safety and efficacy results, therapeutic
potential, collaborations and market opportunities. These
forward-looking statements are based on management's current
expectations. Actual results could differ from those projected in
any forward-looking statements due to several risk factors. Such
factors include, among others, risks and uncertainties related to
our limited operating history; our significant losses incurred
since inception and expectation to incur significant additional
losses for the foreseeable future; the development of our initial
product candidates, upon which our business is highly dependent;
the impact of the COVID-19 pandemic on our operations and clinical
activities; our need for additional funding and our cash runway;
the lengthy, expensive, and uncertain process of clinical drug
development, including uncertain outcomes of clinical trials and
potential delays in regulatory approval; our ability to maintain
our relationships with our third party vendors and strategic
collaborators; and protection of our proprietary technology,
intellectual property portfolio and the confidentiality of our
trade secrets. These and other important factors discussed under
the caption "Risk Factors" in our most recent Annual Report on Form
10-K and other filings with the U.S. Securities and Exchange
Commission could cause actual results to differ materially from
those indicated by the forward-looking statements. Any
forward-looking statements represent management's estimates as of
this date and we undertake no duty to update these forward-looking
statements, whether as a result of new information, the occurrence
of current events, or otherwise, unless required by law.
Certain information contained in this press release relates to
or is based on studies, publications, surveys and other data
obtained from third-party sources and our own internal estimates
and research. While we believe these third-party sources to be
reliable as of the date of this press release, we have not
independently verified, and we make no representation as to the
adequacy, fairness, accuracy or completeness of any information
obtained from third-party sources.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505005207/en/
SQZ Contacts Media John
Lacey 781-392-5514 john.lacey@sqzbiotech.com
Investors Michael Kaiser
857-760-0398 michael.kaiser@sqzbiotech.com
STEMCELL Contacts Public
Relations Dominika Nackiewicz
public.relations@stemcell.com
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
SQZ Biotechnologies (NYSE:SQZ)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024